Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts

Journal of Cancer Research and Clinical Oncology

Volumn 124, Issue 1, 1998, Pages 19-26

  Arguello, Francisco ^a,b   Alexander, Mark A ^a   Greene Jr , John F ^c   Stinson, Sherman F ^a   Jorden, Jean L ^a   Smith, Erik M ^a   Kalavar, Naina T ^a   Alvord, W Gregory ^a   Klabansky, Richard L ^a   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Scott and White Clinic ^*  (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Brain tumor; Ellipticinium; Glioma; Human tumor xenograft; Preclinical evaluation

Indexed keywords

9 CHLORO 2 METHYLELLIPTICINIUM ACETATE; AMINOTRANSFERASE; CARMUSTINE; CISPLATIN; ELLIPTICINE DERIVATIVE; ETOPOSIDE; LIVER ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OSMOTIC MINIPUMP; PLASMA CLEARANCE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARMUSTINE; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; ELLIPTICINES; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIVER DISEASES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

EID: 15444353067     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050128     Document Type: Article

References (26)

1. Acton EM, Narayanan VL, Rishood PA, Shoemaker RH, Vistica D, Boyd MR (1994) Anticancer specificity of some ellipticinium salts against human brain tumors in vitro. J Med Chem 37:2185-2189
2. Anderson WK, Gopalsamy A, Reddy PS (1994) Design, synthesis, and study of 9-substituted ellipticine and 2-methylellipticinium analogues as potential CNS-selective antitumor agents. J Med Chem 37:1955-1963
3. Arguello F, Baggs RB, Graves BT, Harwell SE, Cohen HJ (1992) Effect of IL-1 on experimental bone/bone marrow metastases. Int J Cancer 52:802-807
4. Blasberg RG, Groothuis D (1986) Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 13:70-82
5. Boyd MR (1993) The future of new drug development. In: Niederhuber JE (ed.) Current therapy in oncology. Decker, Philadelphia, pp 11-22
6. Clarysse A, Brugarolas A, Siegenthaler P, Abele R, Cavalli F, De Jager R, Renard G, Rozencweigh M, Hansen HH (1984) Phase II study of 9-hydroxy-2N-methylellipticinium acetate. Eur J Cancer Clin Oncol 20:243-247
7. Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB (1995) Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interaction by fluorescence spectroscopy. J Biol Chem 270:14 998-15 004
8. Gribble GL (1990) Synthesis and antitumor activity of ellipticine alkaloids and related compounds. In: Brossi A (ed) The alkaloids, chemistry and pharmacology, vol 39. Academic Press, San Diego, pp 239-352
9. Gouyette A, Huertas D, Droz JP, Rouesse J, Amiel JL (1982) Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). Eur J Cancer Clin Oncol 18:1285-1292
10. Heideman RL, Packer RJ, Albright LA, Freeman CR, Rotke LB (1993) The tumors of the central nervous system. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott, Philadelphia, pp 633-681
11. Holliwell TR, Yeung JH, Park BK (1985) Hepatic necrosis and glutathione depletion in captopril-treated mice. Br J Exp Pathol 66:67-78
12. Jurayj J, Haugwitz RD, Varma RK, Paull KD, Barret JF, Cushman M (1994) Design synthesis of ellipticinium salts and 1,2-dihydroellipticines with high selectivities against human CNS cancers in vitro. Med Chem 37:2190-2197
13. Kansal VK, Potier P (1986) The biogenetic, synthetic, and biochemical aspects of ellipticine, an antitumor alkaloid. Tetrahedron 42:2389-2408
14. Kenney S, Vistica DT, Linden H, Boyd MR (1995) Uptake and cytotoxicity of 9-methoxy-N2-methylellipticinium acetate in human brain and non-brain tumor cell lines. Biochem Pharmacol 49:23-32
15. Levin VA, Patlak CS, Landahl HD (1980) Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 8:257-296
16. Levin VA, Gutin PH, Leibel S (1993) Neoplasms of the central nervous system. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott, Philadelphia, pp 1679-1737
17. Neuwelt EA, Frenkel EP, D'Agostine AN, Carney DN, Minna JD, Barnett PA, McCormick CI (1985) Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res 45:2827-2833
18. Rall D, Zubrod C (1962) Mechanisms of drug absorption and excretion: passage of drugs in and out the central nervous system. Annu Rev Pharmacol 2:109-128
19. Reddy CS, Hayes AW, Williams WL, Ciegler A (1979) Toxicity of secalonic acid D. J Toxicol Environ Health 5:1159-1169
20. Riou JF, Grondard L, Naudin A, Bailly C (1995) Effect of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity. Biochem Pharmacol 50:424-428
21. Shoemaker RH, Balaschack MS, Alexander MA, Boyd MR (1995) Therapeutic activity of 9-chloro-2-methylellipticinium acetate in an orthotopic model of human brain cancer. Oncol Rep 2:663-667
22. Stinson SF, Alley MC, Koop WC, Fiebig HH, Mullendore LA, Pittman AF, Kenney S, Keller J, Boyd MR (1992) Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 12:1035-1054
23. Strauss LC, Killmond TM, Carson BS, Maria BL, Wharam MD, Leventhal BG (1991) Efficacy of postoperative chemotherapy using cisplatin plus etoposide in young children with brain tumors. Med Pediatr Oncol 19:16-21
24. Van-Bac N, Moisand C, Gouyette A, Muzard G, Dat-Xuong N, Le Pec JP, Paoletti C (1980) Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals. Cancer Treat Rep 64:879-887
25. Vistica DT, Kenney S, Hursey ML, Boyd MR (1994) Cellular uptake as a determinant of cytotoxicity of quaternized ellipticines to human brain tumor cells. Biochem Biophys Res Commun 200:1762-1768
26. Yoshida J, Sugita K, Kobayashi T, Takakura K, Shitara N, Matsutani M, Tanaka R, Nagai H, Yamada H, Yamashita J (1993) Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16). Acta Neurochir (Wien) 120:111-117